Details of the Drug

General Information of Drug (ID: DM2AR7L)

Drug Name
Meloxicam
Synonyms Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica
Indication
Disease Entry ICD 11 Status REF
Arthritis FA20 Approved [1], [2], [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 351.4
Topological Polar Surface Area (xlogp) 3
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 5C6 h [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability
The bioavailability of drug is 89% [4]
Clearance
The total clearance of drug is 0.42C0.48 L/h [6]
Elimination
0.25% of drug is excreted from urine in the unchanged form, and 1.6% of the parent drug is excreted in the feces [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 hours [7]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.71143 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.003% [9]
Vd
The volume of distribution (Vd) of drug is 10-15 L [10]
Water Solubility
The ability of drug to dissolve in water is measured as 0.012 mg/mL [5]
Chemical Identifiers
Formula
C14H13N3O4S2
IUPAC Name
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide
Canonical SMILES
CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
InChI
InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
InChIKey
ZRVUJXDFFKFLMG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
54677470
ChEBI ID
CHEBI:6741
CAS Number
71125-38-7
DrugBank ID
DB00814
TTD ID
D0G7FJ
VARIDT ID
DR00199
INTEDE ID
DR1020
ACDINA ID
D00393

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [13]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Arthritis
ICD Disease Classification FA20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.82E-04 -1.35E-01 -5.84E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Meloxicam
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Dexamethasone. Rheumatoid arthritis [FA20] [48]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Meloxicam and Leflunomide. Rheumatoid arthritis [FA20] [49]
Coadministration of a Drug Treating the Disease Different from Meloxicam (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Meloxicam and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [50]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Meloxicam and Repaglinide. Acute diabete complication [5A2Y] [51]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Meloxicam and Glibenclamide. Acute diabete complication [5A2Y] [51]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Meloxicam and Tolazamide. Acute diabete complication [5A2Y] [51]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Meloxicam and Glipizide. Acute diabete complication [5A2Y] [51]
Arn-509 DMT81LZ Moderate Increased metabolism of Meloxicam caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [52]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Meloxicam and Inotersen. Amyloidosis [5D00] [52]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Meloxicam and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [53]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Meloxicam and Cilostazol. Arterial occlusive disease [BD40] [54]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Budesonide. Asthma [CA23] [48]
Ofloxacin DM0VQN3 Moderate Additive CNS stimulant effects by the combination of Meloxicam and Ofloxacin. Bacterial infection [1A00-1C4Z] [55]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Meloxicam and Kanamycin. Bacterial infection [1A00-1C4Z] [56]
Sulfamethoxazole DMB08GE Moderate Decreased metabolism of Meloxicam caused by Sulfamethoxazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [50]
Sparfloxacin DMB4HCT Moderate Additive CNS stimulant effects by the combination of Meloxicam and Sparfloxacin. Bacterial infection [1A00-1C4Z] [55]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Meloxicam and Streptomycin. Bacterial infection [1A00-1C4Z] [56]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Meloxicam and Gemifloxacin. Bacterial infection [1A00-1C4Z] [55]
Norfloxacin DMIZ6W2 Moderate Additive CNS stimulant effects by the combination of Meloxicam and Norfloxacin. Bacterial infection [1A00-1C4Z] [55]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Meloxicam and ABT-492. Bacterial infection [1A00-1C4Z] [55]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Meloxicam and Netilmicin. Bacterial infection [1A00-1C4Z] [56]
Levofloxacin DMS60RB Moderate Additive CNS stimulant effects by the combination of Meloxicam and Levofloxacin. Bacterial infection [1A00-1C4Z] [55]
Lomefloxacin DMVRH9C Moderate Additive CNS stimulant effects by the combination of Meloxicam and Lomefloxacin. Bacterial infection [1A00-1C4Z] [55]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Meloxicam and Etidronic acid. Bone paget disease [FB85] [57]
Risedronate DM5FLTY Moderate Increased risk of nephrotoxicity by the combination of Meloxicam and Risedronate. Bone paget disease [FB85] [57]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Meloxicam and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [58]
Alpelisib DMEXMYK Moderate Increased metabolism of Meloxicam caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Meloxicam and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [54]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Meloxicam and Iodipamide. Cholelithiasis [DC11] [60]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Meloxicam and Levomilnacipran. Chronic pain [MG30] [61]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Meloxicam and Regorafenib. Colorectal cancer [2B91] [52]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Meloxicam and Drospirenone. Contraceptive management [QA21] [62]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Meloxicam and Methoxyflurane. Corneal disease [9A76-9A78] [52]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Meloxicam and Ardeparin. Coronary thrombosis [BA43] [63]
Mifepristone DMGZQEF Moderate Decreased metabolism of Meloxicam caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [64]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Meloxicam caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [65]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Meloxicam caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [66]
MK-8228 DMOB58Q Moderate Increased metabolism of Meloxicam caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [67]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Meloxicam and Danaparoid. Deep vein thrombosis [BD71] [63]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Meloxicam and Rivaroxaban. Deep vein thrombosis [BD71] [68]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Meloxicam and Sertraline. Depression [6A70-6A7Z] [61]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Meloxicam and Vilazodone. Depression [6A70-6A7Z] [61]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Meloxicam and Vortioxetine. Depression [6A70-6A7Z] [61]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Meloxicam and Milnacipran. Depression [6A70-6A7Z] [61]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Meloxicam and Escitalopram. Depression [6A70-6A7Z] [61]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Meloxicam and Clomipramine. Depression [6A70-6A7Z] [61]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Meloxicam and Cannabidiol. Epileptic encephalopathy [8A62] [52]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Meloxicam when combined with Ethacrynic acid. Essential hypertension [BA00] [69]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Meloxicam and Tazemetostat. Follicular lymphoma [2A80] [54]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Meloxicam and Avapritinib. Gastrointestinal stromal tumour [2B5B] [52]
Sulfinpyrazone DMEV954 Moderate Decreased metabolism of Meloxicam caused by Sulfinpyrazone mediated inhibition of CYP450 enzyme. Gout [FA25] [50]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Meloxicam when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [69]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Meloxicam when combined with Bumetanide. Heart failure [BD10-BD1Z] [69]
Rifapentine DMCHV4I Moderate Increased metabolism of Meloxicam caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [70]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Meloxicam and Brentuximab vedotin. Hodgkin lymphoma [2B30] [71]
Etravirine DMGV8QU Moderate Decreased metabolism of Meloxicam caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Meloxicam caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [50]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Meloxicam and Mipomersen. Hyper-lipoproteinaemia [5C80] [73]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Meloxicam and Teriflunomide. Hyper-lipoproteinaemia [5C80] [49]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Meloxicam and BMS-201038. Hyper-lipoproteinaemia [5C80] [74]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Meloxicam when combined with Trichlormethiazide. Hypertension [BA00-BA04] [69]
Hydrochlorothiazide DMUSZHD Moderate Antagonize the effect of Meloxicam when combined with Hydrochlorothiazide. Hypertension [BA00-BA04] [75]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Meloxicam and Dipyridamole. Hypertension [BA00-BA04] [54]
Balsalazide DMO091F Moderate Increased risk of nephrotoxicity by the combination of Meloxicam and Balsalazide. Indeterminate colitis [DD72] [76]
PF-06463922 DMKM7EW Moderate Increased metabolism of Meloxicam caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [50]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Meloxicam and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [77]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Meloxicam and Idelalisib. Mature B-cell leukaemia [2A82] [78]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Meloxicam and Acalabrutinib. Mature B-cell lymphoma [2A85] [79]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Meloxicam and Ibrutinib. Mature B-cell lymphoma [2A85] [80]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Meloxicam and Ponatinib. Mature B-cell lymphoma [2A85] [81]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Meloxicam caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [52]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Meloxicam and Exjade. Mineral absorption/transport disorder [5C64] [82]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Meloxicam and Panobinostat. Multiple myeloma [2A83] [50]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Deflazacort. Muscular dystrophy [8C70] [48]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Meloxicam and Ruxolitinib. Myeloproliferative neoplasm [2A20] [54]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Meloxicam and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [83]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Meloxicam and Prasugrel. Myocardial infarction [BA41-BA43] [52]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Meloxicam and Vorapaxar. Myocardial infarction [BA41-BA43] [84]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Meloxicam and Sibutramine. Obesity [5B80-5B81] [61]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Meloxicam and Dexfenfluramine. Obesity [5B80-5B81] [61]
Polythiazide DMCH80F Moderate Antagonize the effect of Meloxicam when combined with Polythiazide. Oedema [MG29] [69]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Meloxicam caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [85]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Meloxicam and MK-4827. Ovarian cancer [2C73] [52]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Aspirin. Pain [MG30-MG3Z] [86]
Abametapir DM2RX0I Moderate Decreased metabolism of Meloxicam caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [87]
Lefamulin DME6G97 Moderate Decreased metabolism of Meloxicam caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [88]
Enzalutamide DMGL19D Moderate Increased metabolism of Meloxicam caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [89]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Meloxicam and Epoprostenol. Pulmonary hypertension [BB01] [90]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Meloxicam and Iloprost. Pulmonary hypertension [BB01] [90]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Meloxicam and Everolimus. Renal cell carcinoma [2C90] [91]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Meloxicam and Temsirolimus. Renal cell carcinoma [2C90] [91]
Gatifloxacin DMSL679 Moderate Additive CNS stimulant effects by the combination of Meloxicam and Gatifloxacin. Respiratory infection [CA07-CA4Z] [55]
Larotrectinib DM26CQR Moderate Decreased metabolism of Meloxicam caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [50]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [48]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Meloxicam and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [52]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [48]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Pitolisant. Somnolence [MG42] [52]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Meloxicam caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [92]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Meloxicam and Caplacizumab. Thrombocytopenia [3B64] [54]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Meloxicam and Apixaban. Thrombosis [DB61-GB90] [52]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Meloxicam and Cangrelor. Thrombosis [DB61-GB90] [54]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Meloxicam and Brilinta. Thrombosis [DB61-GB90] [52]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Meloxicam and Cabozantinib. Thyroid cancer [2D10] [93]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Meloxicam and Sirolimus. Transplant rejection [NE84] [91]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Meloxicam and Tacrolimus. Transplant rejection [NE84] [91]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Meloxicam and Tolbutamide. Type 2 diabetes mellitus [5A11] [51]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Meloxicam and Olsalazine. Ulcerative colitis [DD71] [76]
Cinoxacin DM4EWNS Moderate Additive CNS stimulant effects by the combination of Meloxicam and Cinoxacin. Urinary tract infection [GC08] [55]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Meloxicam and Betrixaban. Venous thromboembolism [BD72] [94]
⏷ Show the Full List of 107 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearate E00453 2724691 Emulsifying agent; Gelling agent; Glidant; Modified-release agent; Stiffening agent; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Pigment red 5 E00380 82169 Colorant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Sodium citrate dihydrate E00369 71474 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Meloxicam 10 mg capsule 10 mg Oral Capsule Oral
Meloxicam 5 mg capsule 5 mg Oral Capsule Oral
Meloxicam 15 mg tablet 15 mg Oral Tablet Oral
Meloxicam 7.5 mg tablet 7.5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7220).
2 ClinicalTrials.gov (NCT02183155) Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects. U.S. National Institutes of Health.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 FDA Approved Drug Products: ZYNRELEF (bupivacaine and meloxicam) solution
5 BDDCS applied to over 900 drugs
6 FDA approved products: Mobic (meloxicam) oral tablets
7 A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol. 1996 Apr;35 Suppl 1:13-6. doi: 10.1093/rheumatology/35.suppl_1.13.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 Bekker A, Kloepping C, Collingwood S: Meloxicam in the management of post-operative pain: Narrative review. J Anaesthesiol Clin Pharmacol. 2018 Oct-Dec;34(4):450-457. doi: 10.4103/joacp.JOACP_133_18.
11 Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7.
12 Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8.
13 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
14 Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
25 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
26 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
27 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
28 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
29 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
30 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
31 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
32 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
33 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
34 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
35 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
36 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
37 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
38 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
39 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
40 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
41 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
42 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
43 Pfizer. Product Development Pipeline. March 31 2009.
44 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
45 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
46 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
47 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
48 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
49 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
50 Cerner Multum, Inc. "Australian Product Information.".
51 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
52 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
53 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
54 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
55 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
56 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
57 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
58 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
59 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
60 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
61 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
62 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
63 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
64 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
65 Cerner Multum, Inc. "Canadian Product Information.".
66 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
67 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
68 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
69 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
70 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
71 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
72 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
73 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
74 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
75 McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
76 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
77 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
78 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
79 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
80 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
81 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
82 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
83 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
84 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
85 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
86 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
87 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
88 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
89 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
90 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
91 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
92 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
93 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
94 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.